NCT00309543

Brief Summary

This clinical investigation examined the influence of cytostatic chemotherapy with 5-fluorouracil, modulated by biologically active leucovorin, on patients' survival time following surgery for colon carcinoma Stage II.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
636

participants targeted

Target at P75+ for phase_3

Geographic Reach
1 country

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 1993

Completed
12.4 years until next milestone

First Submitted

Initial submission to the registry

March 31, 2006

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 3, 2006

Completed
Last Updated

April 3, 2006

Status Verified

March 1, 2006

First QC Date

March 31, 2006

Last Update Submit

March 31, 2006

Conditions

Keywords

FluorouracilLeucovorinColon cancer

Outcome Measures

Primary Outcomes (1)

  • Overall survival

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with histologically verified, operable colon carcinoma Stage II (RO, T3-4, N0, M0)
  • Age: less than 80 years
  • WHO Performance \> 2
  • Adequate bone marrow reserve, renal and hepatic functions
  • Informed consent

You may not qualify if:

  • Rectal cancer
  • R1or R2 resection; carcinosis peritonei
  • Start of treatment \> 42 days postop; other adjuvant radiotherapy, chemotherapy or immunotherapy
  • Serious concomitant disease, in particular chronically inflammatory large intestine, cardiopathic or metabolic disease, malignant second carcinoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Hospital Guessing

Güssing, Burgenland, 7540, Austria

Location

Hospital Oberpullendorf

Oberpullendorf, Burgenland, 7350, Austria

Location

Hospital BHB St. Veit/Glan, Surgery

Saint Veit A. D. Glan, Carinthia, 9330, Austria

Location

State Hospital Wolfsberg

Wolfsberg, Carinthia, 9400, Austria

Location

Hospital Hainburg

Hainburg an der Donau, Lower Austria, 2410, Austria

Location

Hospital Krems

Krems, Lower Austria, 3500, Austria

Location

Hospital Tulln

Tulln, Lower Austria, 3430, Austria

Location

Hospital Waidhofen/Thaya

Waidhofen A. D. Thaya, Lower Austria, 3830, Austria

Location

Hospital Wiener Neustadt, Surgery

Wiener Neustadt, Lower Austria, 2700, Austria

Location

Paracelsus Medical University Salzburg - Oncology

Salzburg, Salzburg, 5020, Austria

Location

Medical University of Graz, Oncology

Graz, Styria, 8036, Austria

Location

State Hospital Leoben

Leoben, Styria, 8700, Austria

Location

Hospital St. Vinzenz

Zams, Tyrol, 6511, Austria

Location

State Hospital Kirchdorf

Kirchdorf, Upper Austria, 4560, Austria

Location

Hospital Kreuzschwestern Wels

Wels, Upper Austria, 4600, Austria

Location

Medical University Vienna, General Hospital

Vienna, Vienna, 1090, Austria

Location

Wilheminenspital, Internal Medicin I

Vienna, Vienna, 1160, Austria

Location

State Hospital Feldkirch

Feldkirch, Vorarlberg, 6807, Austria

Location

Related Links

MeSH Terms

Conditions

Colonic Neoplasms

Interventions

FluorouracilLeucovorin

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

UracilPyrimidinonesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsFormyltetrahydrofolatesTetrahydrofolatesFolic AcidPterinsPteridinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingCoenzymesEnzymes and Coenzymes

Study Officials

  • Raimund Jakesz, MD

    Austrian Breast & Colorectal Cancer Study Group

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NETWORK

Study Record Dates

First Submitted

March 31, 2006

First Posted

April 3, 2006

Study Start

November 1, 1993

Last Updated

April 3, 2006

Record last verified: 2006-03

Locations